TD Cowen analyst Dan Brennan lowered the firm’s price target on Danaher (DHR) to $260 from $315 and keeps a Buy rating on the shares. The firm had good Q4 results but was spoiled by weaker guidance and noting the Bioprocess recovery impact has been mitigated by several factors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR: